Brevan Howard Capital Management’s Fate Therapeutics FATE Stock Holding History

Brevan Howard Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,636	Closed	-$40.6K	–	1256
2024 Q4	$40.6K	Buy	+24,636	New	+$62.1K	﹤0.01%	989
2024 Q3	–	Sell	-24,223	Closed	-$79.5K	–	1230
2024 Q2	$79.5K	Buy	+24,223	New	+$106K	﹤0.01%	984
2024 Q1	–	Sell	-38,230	Closed	-$143K	–	1107
2023 Q4	$143K	Buy	38,230 +20,893	+121%	+$49.3K	﹤0.01%	921
2023 Q3	$36.8K	Buy	+17,337	New	+$57.4K	﹤0.01%	371

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Brevan Howard Capital Management's FATE Position: Q1 2025 in Review

Brevan Howard Capital Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 24,636 shares — an estimated $40.6K sold.

Brevan Howard Capital Management first reported a position in FATE in Q3 2023 and held it in 4 quarters. The position peaked at $143K in Q4 2023. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

Brevan Howard Capital Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 24,636 Fate Therapeutics shares in Q1 2025, an estimated $40.6K.
Brevan Howard Capital Management first reported a position in Fate Therapeutics in Q3 2023 and held it in 4 quarters.
Brevan Howard Capital Management's Fate Therapeutics position peaked at $143K in Q4 2023.
132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Brevan Howard Capital Management's 13F filing for Q1 2025, filed 15 May 2025.